Bio-Techne Corp

TECH: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
c%LOCK|^#pG^LOCK|DvLh%QHY

Bio-Techne Earnings: Reasonable Growth Despite Lower Cell Therapy Demand

Bio-Techne reported flat revenue year on year for its second fiscal quarter, while adjusted operating margin increased 100 basis points to 31.1%. Organic revenue growth for protein sciences was 1%, while diagnostics and spatial biology was 3%.

Sponsor Center